Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for IRESSA
- Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
- Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
- Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
- Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
- the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)
- Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients
- Bone Metastasis on the Survival of Gefitinib Effective Patients
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
- A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
- Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
- Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
- Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
- Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
- A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
- PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
- Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
- Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
- Overcoming Endocrine Resistance in Metastatic Breast Cancer
- A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
- Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
- GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
- Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
- Blood Detection of EGFR Mutation For Iressa Treatment
- Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
- Combination of Chemotherapy and Gefitinib as First-line Treatment
- Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients
- Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
- Third-line Treatment of Gefitinib in NSCLC Patients
- Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC
- ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
- Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
- Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
- Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma
- A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR
- A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
- Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
- First Line Gefitinib by FDG-PET Metabolic Response
- Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
- Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer
- Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
- A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
- Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib
- Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
- Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
- Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
- Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
- Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
- Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Local
- Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
- Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
- Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
- UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer
- Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
- Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
- A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
- Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
- A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
- Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations
- Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)
- Hydroxychloroquine and Gefitinib to Treat Lung Cancer
- An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
- Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
- An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
- Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment
- Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
- Ph II Early BC Pre-Surgical Biologic Study
- Open-Label Extension of Other SZ1839 (Iressa) Trials
- Open Label Trial to Assess Iressa in Prostate Cancer Patients
- IRESSA™ (Gefitinib) in Breast Cancer Patients
- Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer
- SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
- Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
- Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
- Iressa Study in Patients With Salivary Gland Cancer
- Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy
- Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
- Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
- Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
- Iressa as Second Line Therapy in Advanced NSCLC-Asia
- Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
- First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
- Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
- A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer
- Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
- Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
- Iressa Follow-up Trial
- Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
- BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
- First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
- Phase II Iressa + Irradiation Followed by Chemo in NSCLC
- ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
- First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
- Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
- Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer
- Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
- Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
- A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer
- Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
- Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
- Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
- Trial of Iressa in Prostate Cancer Patients
- Phase II Iressa & Carbo/Gem in NSCLC
- Iressa v BSC (Best Supportive Care) in First Line NSCLC
- Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
- Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
- Phase II Iressa Versus Vinorelbine (INVITE)
- A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
- The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
- Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
- A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer
- ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
- Iressa 2nd Line Phase III Study in Japan
- Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
- ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
- Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
- Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
- Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
- IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure
- ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
- IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
- Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
- Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
- Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
- Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer
- A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme
- A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
- Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
- Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
- Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
- Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
- A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
- IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer
- A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
- Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
- Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
- Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
- IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
- Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
- Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
- Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
- Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
- Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
- Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
- Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
- Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
- Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
- A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
- Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
- Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
- Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
- Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
- Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC
- Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors
- Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
- Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
- Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer
- Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas
- A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
- ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
- Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
- Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
- Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
- Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
- Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
- Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
- Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
- Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
- Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
- Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer
- Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
- Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
- Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
- Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
- Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
- Iressa Versus Docetaxel (Taxotere)
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
- Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
- Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
- Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
- Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
- Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
- This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
- Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
- ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
- Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
- Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
- Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
- Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
- A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
- Gefitinib in Treating Patients With Cervical Cancer
- Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
- Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
- Iressa/Docetaxel in Non-Small-Cell Lung Cancer
- Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
- Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
- Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Gefitinib in Treating Children With Refractory Solid Tumors
- Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
- Iressa Expanded Access Program (EAP)
- Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
- ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
- Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
- Gefitinib in Treating Patients With Malignant Mesothelioma
- Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
- ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
- Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
- Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
- Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
- Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
- ZD 1839 in Treating Patients With Metastatic Kidney Cancer
- ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
- Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Clinical trials list
click for details